Purpose Of Review: This article provides an overview of the neurologic side effects of commonly prescribed medications, some of which can result in significant impairment if not addressed. This article aims to help clinicians recognize neurologic adverse drug reactions of a range of medication classes.
Recent Findings: Adverse drug reactions are a source of significant morbidity and rising health care costs. Failure to recognize neurologic adverse drug reactions may prompt unnecessary testing to identify a primary neurologic condition and expose the patient to continued adverse effects of a medication. Familiarity with the side effect profiles of newer medications, timing of side effects, pattern of reaction, medication rechallenge, and concurrent medical issues and awareness of significant medication interactions may aid in the identification of a medication side effect.
Summary: Early recognition of neurologic adverse medication reactions can be challenging but is essential to prompt discontinuation of the offending medication or administration of specific symptomatic treatments in select cases. A high index of suspicion is needed to arrive at the correct diagnosis promptly, initiate a treatment plan, limit unnecessary testing, and reduce overall health care cost burden.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1212/CON.0000000000000854 | DOI Listing |
J Mol Histol
January 2025
Clinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Type 2 diabetes mellitus (T2DM) adversely affects various organs, including the brain and its blood barrier. In addition to the brain, hyperglycemia damages the testes. The testes possess blood-tissue barriers that share common characteristics and proteins with the blood-brain barrier (BBB), including breast cancer-resistant protein (BCRP).
View Article and Find Full Text PDFBMJ Open
January 2025
Department of Health Sciences, Brunel University of London, Uxbridge, UK
Objective: To investigate the safety, feasibility and acceptability of the Neurofenix platform for upper-limb rehabilitation in acute and subacute stroke.
Design: A feasibility randomised controlled trial with a parallel process evaluation.
Setting: Acute Stroke Unit and participants' homes (London, UK).
Pediatr Neurol
January 2025
Division of Pediatric Neurology, Department of Neurology, University of Virginia, Charlottesville, Virginia. Electronic address:
Background: Fingolimod and ocrelizumab are approved treatments for adults with multiple sclerosis (MS); however, only fingolimod is approved by the Food and Drug Administration for the treatment of pediatric MS. Currently, there are limited data for the safety and efficacy of ocrelizumab use in children.
Methods: This retrospective cohort study included patients with relapsing-remitting MS who started either ocrelizumab or fingolimod before age 18 years.
J Neurointerv Surg
January 2025
Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany
Background: Intrasaccular devices have broadened treatment options for wide necked aneurysms. This study presents the preliminary experience with the Artisse 2.0 device.
View Article and Find Full Text PDFCrit Care Sci
January 2025
Department of Neurointensive Care, Instituto Estadual do Cérebro Paulo Niemeyer - Rio de Janeiro (RJ), Brazil.
Objective: To define the incidence of ventriculostomy-associated infections and their impact on the mortality and functional outcomes of patients with aneurysmal subarachnoid hemorrhage.
Methods: We prospectively included all consecutive adult aneurysmal subarachnoid hemorrhage patients admitted to the neurological intensive care units of the Instituto Estadual do Cérebro Paulo Niemeyer (Rio de Janeiro, Brazil) and Hospital Cristo Redentor (Rio Grande do Sul, Brazil) who required external ventricular drains from July 2015 to December 2020. Daily clinical and laboratory variables were collected at admission and during the hospital stay.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!